Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirogabalin + EBMP vs EBMP Alone for IC/BPS
NCT07803393Phase 1Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2026
01
Overview
Phase 1, randomised, single-blind trial of mirogabalin in interstitial cystitis (IC) and bladder pain syndrome (BPS) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Global Response Assessment at 12 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mirogabalin
03
Conditions
interstitial cystitis (IC)bladder pain syndrome (BPS)
Beyond the preview
Go deeper on NCT07803393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803393.